G6PD and methemoglobinemia: However, the drug is used infrequently because of concerns about its oxidative side effects causing intravascular hemolysis and methemoglobinemia in populations in whom glucose-6-phosphate dehydrogenase (G6PD) deficiency is common and facilities for assessing G6PD status are not readily available (ie, most malaria-endemic areas).